The EUROMALVAC2 consortium will develop malaria vaccines inducing protective antibody responses to P.falciparum bloodstage antigens, moving leading vaccine candidates towards GMP-production and clinical trial whilst validating 2nd and 3rd generation candidates in its malaria vaccine R&D 'pipeline '. The major projects within the EUROMALVAC2 work programme involve; a. Optimisation of synthesis of lead candidate malaria vaccines based on merozoite surface protein 1 (MSPl) and the apical merozoite antigen 1 (AMAl). b. Production and testing of more parasitised erythrocyte membrane protein (PfEMP-l) based vaccines. c. Production and testing of new vaccine formulations based on the N-terminal Block 2 sequences of MSP1 and on other, less well characterised merozoite antigens. d. Development of a transmission blocking vaccine based on gametocyte antigen Pfs48/45. e. Strengthening of preclinical and clinical testing facilities.
Funding SchemeCSC - Cost-sharing contracts
HG3 1PY Harrogate
2288 GJ Rijswijk Zh
69210 St Germain Sur L'arbresle
NW7 1AA London
6500 HB Nijmegen
171 82 Solna